Literature DB >> 2139341

Antibody response after hepatitis B immunisation in a group of health care workers.

A Cockcroft1, P Soper, C Insall, Y Kennard, S Chapman, C Gooch, P Griffiths.   

Abstract

Hepatitis B immunisation has been offered to staff of Hampstead Health Authority since 1982 and is now offered to all staff with clinical contact. Three doses of 20 micrograms of vaccine are given at zero, one, and six months and the antibody response is measured three months later. Results were analysed to seek for associations with the antibody response. At the time of analysis, 2739 people had started vaccination and 1067 had completed the course and had a measurement of antibody response. Vaccine injections were initially into the buttock and later into the arm; measurement of antibody levels was initially by radioimmunoassay (RIA) and later by enzyme immunoassay (EIA). A positive antibody response was defined as a positive/negative ratio of greater than 10 for RIA or a level of greater than 10 mIU/ml for EIA. Associations between antibody response and other variables were tested by chi 2 and a multiple logistic regression analysis was undertaken to examine the effects of variables in combination. The overall antibody response rate was 95%. Men and women did not respond differently but there were significantly more positive responses with the EIA testing method and a tendency for more positive responses with arm injections. The responders were significantly younger than the non-responders and had significantly lower values of body mass index (wt/ht2).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139341      PMCID: PMC1035132          DOI: 10.1136/oem.47.3.199

Source DB:  PubMed          Journal:  Br J Ind Med        ISSN: 0007-1072


  6 in total

1.  Alterations in the immune response of nonresponders to the hepatitis B vaccine.

Authors:  M J Nowicki; M J Tong; R E Bohman
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

2.  Efficacy of hepatitis B vaccine.

Authors:  A D Campbell; M H Hambling; P A Pinnington; E Lees
Journal:  J Soc Occup Med       Date:  1988 Spring-Summer

3.  Aspects of vaccination against hepatitis B; passive-active immunization schedules and vaccination responses in different age groups.

Authors:  F Deinhardt
Journal:  Scand J Infect Dis Suppl       Date:  1983

4.  The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men.

Authors:  D P Francis; S C Hadler; S E Thompson; J E Maynard; D G Ostrow; N Altman; E H Braff; P O'Malley; D Hawkins; F N Judson; K Penley; T Nylund; G Christie; F Meyers; J N Moore; A Gardner; I L Doto; J H Miller; G H Reynolds; B L Murphy; C A Schable; B T Clark; J W Curran; A G Redeker
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

5.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

6.  Hepatitis B vaccine: immunogenicity and follow-up including two year booster doses in high-risk health care personnel in a London teaching hospital.

Authors:  E A Fagan; P Tolley; H M Smith; M P Peters; J Coleman; P Elliott; R Williams; A L Eddleston
Journal:  J Med Virol       Date:  1987-01       Impact factor: 2.327

  6 in total
  3 in total

1.  Anti HBs protection in hospital workers vaccinated against hepatitis B: policy implications of a pilot study.

Authors:  A Yassi; M McGill; S Jeanson
Journal:  Br J Ind Med       Date:  1990-09

2.  Antibody response to hepatitis B vaccination.

Authors:  H A Waldron
Journal:  Br J Ind Med       Date:  1990-05

3.  Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection.

Authors:  Alicja E Grzegorzewska; Piotr M Wobszal; Anna Sowińska; Adrianna Mostowska; Paweł P Jagodziński
Journal:  Mol Biol Rep       Date:  2013-10-25       Impact factor: 2.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.